A Monoclonal Antibody, Nimotuzumab, as Treatment for Recurrent or Metastatic Cervical Cancer

Uterine Cervical Cancer Clinical Trial

Official title:

Phase I-II Study of Palliative Treatment With Nimotuzumab as a Second, Third Line or More of Treatment for Advanced or Metastatic Cervical Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02095119
• Other study ID #: INCAN/CC/130/09
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: February 17, 2014
• Last updated: April 13, 2015
• Start date: July 2008
• Est. completion date: March 2014

Study information

• Verified date: April 2015
• Source: National Institute of Cancerología
• Contact: n/a
• Is FDA regulated: No
• Health authority: Mexico: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

The following is an open label, non comparative, pilot study of palliative treatment as a second, third line or more of treatment in patients with recurrent, persistent or Metastatic Cervical Cancer; it has a limited sample of 15 patients with the primary goal of evaluating the response (defined as: Complete, partial or stable disease) to treatment with a Monoclonal Antibody, Nimotuzumab, on a weekly basis + CDDP 50mg/m2/BSA as a single agent every 3 weeks for patients with good renal function (Creatinine clearance => 60) or Gemcitabine 800 mg/m2/BSA in patients with renal failure (Creatinine clearance <60).

Secondary objectives consist of evaluating disease-free survival, overall survival and assess patient tolerance to treatment with Nimotuzumab.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: March 2014
• Est. primary completion date: December 2013
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Diagnostic criteria:

• Female patients in whom a diagnosis of cervical cancer of epithelial origin has been confirmed by histologic and/or radiologic assessment.

• Said patients must be in relapse or persistency after receiving first line chemo-radiotherapy and one or more lines of palliative chemotherapy.

• Karnofsky score of 80 or more.

• A CT scan will be performed in all patients to assess measurable target lesions.

• The clinical diagnosis must be evaluated by more than clinical investigator

Inclusion Criteria:

• Patients who give their written consent of participation in this study.

• Patients with recurrent or persistent cervical-uterine cancer, with local and/or systemic disease with measurable lesions, whether by physical examination, CT Scan or MRI detected at least in the previous 6 weeks. If there is only one lesion and it is less than 10 mm in length, a biopsy confirmation is required.

• Patients currently receiving a second, third line or more of palliative chemotherapy diagnosed at least 30 days after the last chemotherapy.

• Patients with one of the following Histopathological reports: Squamous Cell Carcinoma (epidermoid carcinoma), adenocarcinoma, adenosquamous carcinoma or glassy cell carcinoma.

• Patients must be older than 18 years old.

• ECOG score no worst than 3.

• Patients with life expectancy greater than 4 weeks.

• Patients with left ventricle ejection fraction (LVEF) = 50 measured by radioisotopic ventriculography.

• Patients who meet all previous criteria with previously radiated metastatic disease in the central nervous system will be included.

• Patients with normal functioning of the bone marrow and other organs as defined by the following parameters:

• Hemoglobin = 9 g/L

• Leucocytes = 4000/microL

• Absolute neutrophil count = 1500/microL

• Platelet count = 100000/microL

• Total serum Bilirubin: up to 1.5 times the normal value

• Total Proteins: Within normal limits

• AST and ALT =/< 2.5 times the normal superior limit of the institutional laboratory

• Serum creatinine: within normal limits or up to 2 mg and GFR = 60ml/min calculated with the Cockcroft-Gault equation.

Exclusion Criteria:

• Pregnant or nursing mothers.

• Patients with cervical-uterine cancer with a histopathological report of: small cell carcinoma and/or neuroendocrine tumor.

• Patients currently receiving another investigational onco-specific drug.

• Patients with a history of allergy to chemical substances with similar chemical composition to that of the monoclonal antibody or chemotherapeutic agents used in this study.

• Patients with non-controlled co-morbid states such as active infections, symptomatic congestive heart failure, unstable angina, cardiac arrhythmias, uncompensated diabetes and/or psychiatric illness.

• Presence of a second tumor. With the exception of those patients who have received adequate treatment for skin carcinomas (basal or squamous).

• Previous or concomitant malignancy except non-melanoma skin carcinoma.

• Social, familiar or geographic conditions that suggest poor attachment to the study.

Discontinuation of treatment criteria:

• At the patient´s request.

• Progression of disease causing worsening of the patient´s overall status in non manageable clinical conditions, (ECOG worst than 3).

• Death.

• Discontinuation of monitoring and/or loss of patient follow-up for more than 2 months.

• Severe adverse reaction grade 4 according to CTCAE.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Uterine Cervical Cancer
• Uterine Cervical Neoplasms

Intervention

Drug:
• Nimotuzumab
Monoclonal antibody Nimotuzumab will be administered alone at a 200mg dose weekly during the first 4 weeks. Posteriorly it will be administered with a maintenance dose of 200 mg every 2 weeks in combination with chemotherapeutic agents Cisplatin in patients with good renal function or Gemcitabine in patients with kidney failure data until exclusion or death occurs. The administration will be intravenously in 250 ml of saline solution in a time period of 30 minutes.
• Cisplatin
Cisplatin will be administered at a calculated dose of 50mg/m2/BSA every 21 days as concomitant therapy to Nimotuzumab, until 6 cycles are completed, exclusion or death occurs, only in patients whose creatinine clearance as defined by the Cockcroft-Gault equation is >/= 60. The administration form will be intravenously.
• Gemcitabine
Gemcitabine will be administered at a calculated dose of 800 mg/m2/BSA every 21 days as concomitant therapy to Nimotuzumab, until 6 cycles are completed, exclusion or death occurs, in patients with kidney failure data(Creatinine clearance as defined by the Cockcroft -Gault equation < 60). The administration form will be intravenously.

Procedure:
• CT Scan
A CT Scan will be performed in all patients prior to the beginning of treatment to assess any measurable tumor found by this method. The CT Scan will be repeated once the patient completes the induction phase with Nimotuzumab (4 once a week doses), when the patient has completed 3 full cycles of combination therapy with Nimotuzumab (every 2 weeks)and Gemcitabine or Cisplatin (every 21 days)and once more when the patient has completed 6 full cycles of the aforementioned therapy.

Locations

Country	Name	City	State
Mexico	Instituto Nacional de Cancerología	Mexico City	Federal District

Sponsors (1)

Lead Sponsor	Collaborator
National Institute of Cancerología

Country where clinical trial is conducted

Mexico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Antitumoral Response	Treatment response will be evaluated according to the new International Criteria from Response Evaluation Committee in Solid Tumors (RESIST). Antitumoral response will be evaluated from patient´s inclusion after 4 weeks of induction therapy and then every 3 months until second year of follow up for each patient.	After 4 weeks of induction therapy, and then every 3 months for a period of 2 years	No
Secondary	Progression Free Survival	Progression Free Survival will be defined as the time elapsed since the beginning of interventions until progressive disease is documented by growth of measurable lesions or new lesions on CT Scan or MRI according to the response evaluation criteria in solid tumors (JNCI 92 (3): 205-216, 2000).	After patient´s inclusion every 3 months for a period 2 years	No
Secondary	Overall Survival	Patient´s survival since inclusion until death	from patient´s inclusion until 24 months	No
Secondary	Drug Toxicity	Drug toxicity will be assessed with hematologic, renal and hepatic laboratory measures as well as patient symptomatology and physical findings. Any abnormality in these parameters will be reported as an adverse event according to the Common Terminology Criteria for Adverse Events version 3.0(CTCAEV3.0, 2006)	from patient´s inclusion every 2 weeks for a period of 2 years	Yes